Serum circulating miRNA-342-3p as a potential diagnostic biomarker in parathyroid carcinomas: A pilot study

Endocrinol Diabetes Metab. 2021 Oct;4(4):e00284. doi: 10.1002/edm2.284. Epub 2021 Jul 29.

Abstract

Objective: To compare the serum miRNA expression profiles between patients with benign and malignant parathyroid tumours.

Background: Despite recent advances in molecular biology, a histological tissue biopsy is still the method of choice used to diagnose most cancers. The preoperative cytology is not an applicable method for diagnosis of parathyroid cancer (PC); therefore, huge interest exists in terms of finding alternative methodologies to seek specific cancer biomarkers.

Design: A retrospective cross-sectional study.

Patients and methods: Serum samples of patients with PC (n = 13) and parathyroid adenoma (PA) (n = 11), age (p = .999) and sex (p = .999) were matched and examined via the simultaneous comparative expression analysis of 754 microRNAs (miRNAs). The «TaqMan OpenArray Human MicroRNA Panel» (Applied Biosystems) was used to conduct real-time PCRs using the «QuantStudio 12К Flex» station (Life Technologies).

Results: According to the results of a pilot study, significant changes in expression levels between the PC group and the PA group (control) (p < .05) were observed for 17 miRNAs. Among them, the downregulation of miRNA-342-3p met the Benjamini-Hochberg adjustment criteria for multiple comparisons (p = .02).

Conclusions: Serum miRNA-342-3p could be a promising biomarker for PC to improve diagnosis and prognosis.

Keywords: microRNAs; parathyroid carcinoma; parathyroid gland.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Cross-Sectional Studies
  • Humans
  • MicroRNAs* / genetics
  • Parathyroid Neoplasms* / diagnosis
  • Parathyroid Neoplasms* / genetics
  • Pilot Projects
  • Retrospective Studies

Substances

  • Biomarkers, Tumor
  • MIRN342 microRNA, human
  • MicroRNAs